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A B S T R A C T
Doppler can evaluate renal vascular resistance, and resistance index (RI) highly correlates with blood pressure and
renal function in various pathological conditions. Purpose of the study was to measure and compare renal Doppler indi-
ces in patients with newly-diagnosed essential hypertension (EH) and in healthy subjects; to determine changes of Dopp-
ler indices in patients after six-months monotherapy with either the AT II blocker (valsartane) or calcium channel blo-
cker (niphedipine); to determine which drug has better renoprotective effect. 65 healthy controls were examined, as well
as 69 patients with the newly-diagnosed EH, without signs of the target organ damage. Duplex Doppler US of interlobar
intrarenal arteries was performed, and RI, acceleration index (AI) and acceleration time (AT) measured. Antihyper-
tensive monotherapy was performed with vaslartane in 34 patients and with niphedipine in 35 patients. Doppler was re-
peated after the six-months therapy. RI in patients with the 1. stage of EH is significantly higher compared to the controls
(p<0.001), and significantly lower compared to the stage 2. of EH (p<0.001). The significant decrease of systolic (p<0.001)
and dyastolic blood pressure (BP) (p<0.001) was noted after the therapy. RI in healthy examinees (RI=0.59±0.023) is
significantly lower than in EH (RI=0.66±0.26) (p<0.001), while AI is significantly higher (p<0.001), and AT is signifi-
cantly lower (p<0.001). In patients treated with valsartane and those treated with niphedipine, the RIs are significantly
lower than before (p<0.001), while AIs were significantly higher, and ATs were significantly lower after the therapy after
the therapy with both drugs. RIs in patients treated with valsartane (RI = 0.615 ± 0.036) are significantly lower than RIs
of patients treated with niphedipine (RI=0.642±0.030) (p<0.01) after therapy. Regression analysis for the predictive val-
ues of RI, AT, AI in relation to the age-standardized values of systolic and diastolic BP of healthy examinees and patients
with hypertension has demonstrated that RI is the strongest and statistically significant predictor in all groups of exa-
minees. Six-months monotherapy of EH with valsartane or with niphedipine is equally efficient in the decrease of the
blood pressure, but valsartane has more favourable effect on kidney. Resistance index measured in intrarenal arteries is
the best parameter of Doppler spectrum in the evaluation of the effects of antihypertensive therapy on the kidney.
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Introduction
Hypertension is the major risk-factor for the develop-
ment of cardiovascular diseases, and the most important
goal of the antihypertensive treatment is to prevent the
cardiovascular morbidity and mortality. Large clinical
studies have conclusively demonstrated that lowering of
the blood pressure reduces the risk of major cardiovascu-
lar events1,2, although only approximately one third of
hypertensive patients obtain adequate medical regula-
tion of blood pressure3. Additional risk factors, like ele-
vated blood cholesterol level, diabetes, smoking, and re-
nal disease affect the outcome of hypertension4. Even the
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mild renal insufficiency is associated with the additional
cardiovascular events in hypertensive patients5. The most
important system for the regulation of blood pressure
and water and sodium metabolism is the renin-angioten-
sine system. Renin is the enzyme secreted by the kidney
iuxtaglomerular system and is associated with the se-
creation of aldosterone and production of the angiotensin
II6. Antihypertensive medications are very numerous,
and their effects on kidneys are studied in numerous
publications. Patients with uncomplicated hypertension
are usually treated with monotherapy, while patients
with complicated hypertension need therapy with two or
more medications to achive sattisfactory blood pressure
control2,6–9. The most common hypertensive lesions of re-
nal blood vessels are atherosclerotic lesions of afferent
and efferent arteriolae and glomerular capillaries, that
result in the decrease of glomerular filtration and tubu-
lar dysfunction10,11. One of the hystopathologic changes
observed is myointimal hyperplasisa of interlobular ar-
teries, with the reduction of arterial lumen. Also focal or
global segmental sclerosis is observed. Nephroangioscle-
rosis results in elevated renal vascular resistance12,13.
Color duplex Doppler ultrasound can demonstrate blood
flow in intrarenal arteries and enables estimation of re-
nal vascular resistance bymeasuring renal resistance index
(RI) after spectral waveform analysis is performed14,15.
The aims of the study are following: (1) to measure
the Doppler resistance index (RI), acceleration time (AT)
and acceleration index (AI) in interlobar intrarenal ar-
teries of patients with the newly diagnosed essential
hypertenison and in the control group of healthy subjects
and evalute differences between these groups; (2) to de-
termine changes of RI, AT, AI of hypertensive patients af-
ter six-months monotherapy with AT II blocker (val-
sartane) or with calcium-channel blocker (niphedipine);
(3) to determine which of the two antihypertensive medi-
cations has better effect on analyzed Doppler parame-
ters, i.e. better therapeutic effect on the kidney.
Materials and Methods
Sixty-nine patients with newly diagnosed essential
hypertension (30 women, 39 men, average age 49.6 years,
range 35–60 years) were included into the study. They
were examined in the period of 44 months. The diagnosis
of essential hypertension was established after the metic-
ulous hisotry, physical exam, complete laboratory analy-
sis of blood and urine. The presence and the degree of the
damage of target organs were evaluated by ECG, ocular
fundus exam and urinalysis; patients with the evidence
of the target organ damage were excluded from the study.
In all patients B-mode and color-duplex Doppler US
exam of kidneys and renal arteries was performed. Addi-
tional tests were performed to exclude secondary hyper-
tension when necessary. All patients with ultrasound
findings suggesting secondary hypertension (evidence
for renal artery stenosis, asymmetry in renal size – dif-
ference of renal length >2 cm, hyperechoic renal paren-
chyma, masses in adrenal glands, hydronephrosis, etc.)
were excluded from the study. Hypertension was defined
according to the JNC VII (Seventh Report of the Joint
National Committee on Prevention, Detection, Evalua-
tion and Treatment of High Blood Pressure) criteria as
average blood pressure 140/90 mmHg in at least three
measures in various situations, and patients were in-
cluded into the study with the first and second degree of
hypertension according to the JNC VII criteria2, which is
equivalent to the mild and moderate hypertension ac-
cording to the ESH/ESC (European Society of Hyperten-
sion and European Society of Cardiology) classification16,17.
Informed consent was obtained by all examinees, and In-
stitutional Ethical Board consented with the study. Pa-
tients were excluded from the study with tumors, liver
diseases, chronic cardiac failure, diabetes mellitus, renal
insufficiency, obese people (body mass index >30), patients
with psychological diseases, dementia, and other diseases
that render examinees uncooperable. Patients were on
the normal diet, with no salt restriction, and were not
treated by antihypertensive medications previously.
The control group of healthy examinees, mostly vol-
unteers, consists of 65 healthy subjects (25 women and
40 men, average age 47.1 years, range 36–60 years), who
are normotensive, without acute or chronic diseases in
history that could affect renal circulation (absence of re-
nal, pulmonary and systemic diseases and diabetes melli-
tus), with normal urinalysis, and normal morphologic
B-mode ultrasound findings of kidneys. All healthy exa-
minees gave informed consent to the study.
Arterial blood pressure (BP) was measured in sitting
position after five minutes of rest. Systolic and diastolic
blood pressure were determined with the precision of 2
mm Hg, and they were measured three times in a row, in
a period of five minutes, and average values of three mea-
surements were taken for the value of systolic and dia-
stolic blood pressure. Hypertension was considered when
BP values were 140/90 mmHg. In all patients BP was
measured on the day when the study commenced, and after
six-months of antihypertensive monotherapy. Patients
were routinelly controlled twice a month to modify the
dose of the medication. Following laboratory tests of
blood and urine were performed: creatinine, urea, potas-
sium, sodium, choloride, uric acid, cholesterol, LDL cho-
lesterol, HDL cholesterol, glucose, ALT, AST, LDH, CPK,
billirubin, complete red and white blood count, complete
urinalysis, creatinine clearance, 24-hours protein excre-
tion in urine. All laboratory analysis were performed us-
ing the standard, established methods in general usage.
Body mass index was calculated according to the for-
mula: body weight (kg)/height2, a patients with the BMI
>30 were considered to be obese.
Antihypertensive monotherapy was performed with
ATII blocker valsartane 80–160 mg (Diovan®, produced
by Novartis) in a group of 34 patients, and with cal-
cium-chanel blocker niphedipine up to 40 mg/daily (Cor-
dipin retard®, produced by Krka) in 35 patients. Dosage
modification was dependant on BP values measured at
the control examinations.
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Ultrasound exams were performed using state-of-the-
-art ultrasound scanners Logiq 9 (General Electric Health-
care, Milwaukee, WI, USA) and HDI 5000 (Advanced
Technology Laboratories, Bothel, WA, USA), equiped
with multifrequency/broad-bandwith convex electronic
transducers in the frequency ragne of 2.5–5 MHz, with
the advanced software capabilities (native harmonic, au-
tomatic image optimization, multiple focal zones, com-
pound imaging, etc). First the B-mode US exam of kid-
neys was performed, and lenght and parenchymal thick-
ness were recorded and evaluated. Only patients with
simple renal cysts with diameter <5 cm were not ex-
cluded, while all other patients with renal abnormalities
were excluded from the study (small kidney, pelvicalie-
ctasis, renal stones, nephrocalcinosis, masses, ADPKD,
etc). After that color duplex Doppler exam was per-
formed in the left or right decubitus postion of the pa-
tient. Spectral waveform analysis was performed in in-
terlobar arteries, at three typical sites (upper, middle and
lower pole of the kidney). Resistance index (RI) was mea-
sured, as well as acceleration time (AT) and acceleration
index (AI). Mean value from all three measurements was
calculated for the each Doppler parameter. All patients
with »parvus-tardus« spectra, indicating renal artery
stenosis, were excluded from the study. RI is the differ-
ence of maximum systolic velocity and minimum dia-
stolic velocity, divided by maximum systolic velocity. AT
is the time from the beginning of the cycle to the early
systolic peak. AI reflects the steepness of the acceleration
phase of spectral curve, and is calculated as Dv/Dt and ex-
pressed in m/s2. The lowest pulse repetition frequency
that does not cause alliasing was used in all measure-
ments. Wall filter <25 Hz was used, as well as maximal
priority lever for color. Angle correction was applied in all
measurements, with the angle between US beam and the
vessel below 60°. Spectra in main renal arteries were also
analyzed and peak systolic velocities measured. They were
<1.5 m/s in all patients. The duration of exams was
30–45 minutes. Only those examinees were included
where optimal intrarenal arterial Doppler spectra could
be demonstrated and all analyzed parameters measured.
Power Doppler was not used since the quality of color
Doppler was excellent and enabled equisite demonstra-
tion of intrarenal flow and of spectral analysis.
The measured values of RI, AT, AI and blood pressure
are expressed as mean values±SD, and median values.
RI, AT and AI values were compared between healthy
controls and group of hypertensive patients before the
commencement of medical treatment. After that, values
of Doppler parameters were compared in each individual
patient at the beginning of treatment, and after six-
-months antihypertensive monotherapy. The changes were
analyzed separately in the group of patients taking AT II
blocker and in the group of patients taking calcium-chan-
nel blocker, and differences between these two groups
were compared.
The distribution of all quantitative variables was
tested in the group and in time for normal distribution
using Smirnov-Kolmogornov test. When distribution was
normal parametric tests were used in the analysis (Stu-
dent’s t-test and t-test for paired samples), while when
distribution was not normal non-parametric tests were
used (Mann-Whitney test, Wilcoxonov paired-rank test).
The differences in distributions of qualitative variables
were tested with c2-test. Predictive value of RI, AT and
AI in relation to the blood pressure as criterium variable
was evaluated by using regression analysis.
Results
Among quantitative variables only distributions of ac-
celeration time (AT) in various combinations (in the
group, before and after the therapy) have demonstrated
distribution which is not normal. All other variables had
normal distribution.
Correlation of RI values and systolic and diastolic
blood pressures were analyzed. In all 134 examinees
(healthy examinees and hypertensive patients before the-
rapy) statistically significant correlation (Pearson’s test)
was observed between RI and systolic blood pressure
(p<0.001, CC 0.93), and between RI and diastolic blood
pressure (p<0.001, CC 0.89). RI has also statistically sig-
nificant correlation with the age (p<0.001, CC 0.54).
The average age of healthy examinees in the control
group was 47.1±7,3 (range 35–60) years, and average age
of hypertensive patients was 49.6±7,1 (range 35–60) years.
Paired T-test has not demonstrated statistically signifi-
cant difference (p=0.06).
The descriptive data for healthy examinees in the
control group (N=65) is shown in Table 1.
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TABLE 1
DESCRIPTIVE DATA FOR HEALTHY EXAMINEES IN THE CONTROL GROUP (N=65)
RI AT (ms) AI (m/s2) Sist (mmHg) Diast (mmHg) Age (years)
X 0.59 21.69 8.06 125.6 73.6 47.1
Median 0.59 20 8 130 72 46
SD 0.023 16.6 0.78 8.93 6.42 7.34
Min 0.55 10 6 105 60 35
Max 0.65 15 9.7 138 86 60
RI – resistance index, AT – acceleration time, AI – acceleration index, Sist – systolic blood pressure, Diast – diastolic blood pressure,
Age, min – minimum, max – maximum
The descriptive data for all hypertensive patients
(N=69) before (0) and after the therapy (1) are pre-
sented in Table 2.
T-test has demonstrated the significant decrease of
systolic blood pressure (p<0.001) and diastolic blood
pressure (p<0.001) after therapy in relation to the val-
ues before the therapy.
T-test has demonstrated statistically significant differ-
ences in values of RI and AI, and Mann-Whitney test
demonstated statistically significant differences in values
of AT between healthy examinees in the control group and
the group of all patients with essential hypertension. RI in
heatlhy examinees (RI=0.59±0.023) is significantly lower
compared to hypertensive patients (RI=0.66±0.26) (p<0.001),
and AI in healthy examinees (AI=8.06±0.78 m/s2) is sig-
nificantly higher than in the hypertensive patients
(AI=5.27±1.47 m/s2) (p<0.001). Acceleration time is
significantly lower in healthy examinees (21.7±16.6 ms)
compared to hypertensive patients (38.6±8 ms)
(p<0.001).
The average age of hypertensive patients treated with
valsartane was 49.7±6.8 years, while average age of hyper-
tensive patients treated with niphedipine was 49.5±7,5
years. Paired T-test has not shown statistically significant
difference (p=0.9).
The descriptive data for hypertensive patients treated
with niphedipine (N=35) before (0) and after therapy (1)
are demonstrated in Table 3.
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TABLE 2
DESCRIPTIVE DATA FOR 69 HYPERTENSIVE PATIENTS BEFORE (0) AND AFTER THE THERAPY (1)
RI-0 RI-1
AT-0
(ms)
AT-1
(ms)
AI-0
(m/s2)
AI-1
(m/s2)
Sist-0
(mmHg)
Sist-1
(mmHg)
Diast-0
(mmHg)
Diast-1
(mmHg)
X 0.659 0.629 38.62 34.57 5.27 6.09 157.9 135.0 99.7 81.3
Median 0.66 0.62 40 30 5 6.0 155 135 100 80
SD 0.026 0.035 8.04 7.94 1.47 1.53 10.15 8.05 5.25 5.87
widctlparMin 0.61 0.56 20 20 3 3.0 142 120 88 70
Max 0.71 0.72 55 50 8.8 8.8 178 160 109 100
RI – resistance index, AT – acceleration time, AI – acceleration index, sist – systolic blood pressure, Diast – diastolic blood pressure,
min – minimum, max – maximum
TABLE 3
DESCRIPTIVE DATA FOR 35 HYPERTENSIVE PATIENTS TREATED WITH NIPHEDIPINE BEFORE (0)
AND AFTER THE THERAPY (1)
RI-0 RI-1
AT-0
(ms)
AT-1
(ms)
AI-0
(m/s2)
AI-1
(m/s2)
Sist-0
(mmHg)
Sist-1
(mmHg)
Diast-0
(mmHg)
Diast-1
(mmHg)
X 0.657 0.642 38.29 35.86 5.27 5.69 158.6 136.4 99.8 81.9
Median 0.65 0.63 40 35 5 5.2 155 135 100 82
SD 0.026 0.03 7.66 7.90 1.58 1.55 9.56 6.83 5.04 5.74
Min 0.61 0.59 20 20 3 3.4 145 120 88 70
Max 0.71 0.70 55 50 8.8 8.4 175 160 108 100
RI – resistance index, AT – acceleration time, AI – acceleration index, sist – systolic blood pressure, Diast – diastolic blood pressure,
min – minimum, max – maximum
TABLE 4
DESCRIPTIVE DATA FOR 34 HYPERTENSIVE PATIENTS TREATED WITH VALSARTANE BEFORE (0)
AND AFTER THE THERAPY (1)
RI-0 RI-1
AT-0
(ms)
AT-1
(ms)
AI-0
(m/s2)
AI-1
(m/s2)
Sist-0
(mmHg)
Sist-1
(mmHg)
Diast-0
(mmHg)
Diast-1
(mmHg)
X 0.661 0.613 38.97 33.24 5.27 6.5 157.3 133.6 99.6 80.7
Median 0.66 0.61 40 30 5.1 6.85 153 135 100 80
SD 0.026 0.036 8.51 7.87 1.36 1.42 10.82 9.02 5.53 6.03
Min 0.61 0.56 20 20 3.2 3.0 142 120 88 70
Max 0.71 0.72 55 50 8.4 8.8 178 160 109 95
RI – resistance index, AT – acceleration time, AI – acceleration index, sist – systolic blood pressure, Diast – diastolic blood pressure,
min – minimum, max – maximum
The descriptive data for hypertensive patients treated
with valsartane (N=34) before (0) and after therapy (1)
are demonstrated in Table 4.
T-test has not shown statistically significant differ-
ences in RI values before the treatment between groups
of hypertensive patients later treated with niphedipine
and with vaslartane (p=0.62). Likewise, t-test has not
shown significant diffrences in values of AI between
these two groups of patients (p=0.99). Mann-Whitney
test has not shown significant differences in values of AI
between these two groups of patients (p=0.71).
In patients treated with valsartane, RI was signifi-
cantly lower after therapy compared to values before the
therapy (t-test, p<0.001). Likewise, in patients treated
with niphedipine RI was significantly lower after therapy
(p<0.001). AI values were significantly higher after ther-
apy both in the valsartane group (t-test, p<0.001) and
niphedipine (t-test, p<0.001). AT values were signifi-
cantly lower (Wilcoxon signed ranks test) after therapy
both in patients treated with valsartane (p<0.001) and
those treated with niphedipine (p<0.003).
The differences in values of RI between patients trea-
ted with valsartane and those treated with niphedipine
were significantly different after six months of therapy.
In patients treated with valsartane mean RI was
0.615±0.036, siginificantly lower than in patients treated
with niphedipine, where mean RI was 0.642±0.030)
(p<0.01, t-test). Likewise, AI in patients treated with
vaslartane (AI=6.5±1.42) was significantly higher than
in patients treated with niphedipine (AI=5.7±1.55)
(p<0.03, t-test).
Mann-Whitney test has not shown significant differ-
ences in values of AT after treatement between patients
treated with valsartane and niphedipine (p=0.19).
All measured varibles (systolic, diastolic and mean BP,
pulse pressure, RI, AT, AI) have positive correlation with
age (p<0.01 for all variables), and all of these values are
age-adjusted. All variables have normal distribution within
the group, which enables regression analysis. Regression
analysis was performed for the predictive values RI, AT,
AI in relation to the age-standardized values of systolic
and diastolic BP of healthy examinees and hypertensive
patients.
The results of regression analysis are demonstrated
in the following Tables 5–8.
It is visible that for age-standardized systolic BP the
significant predictor is age-adjusted resistance index,
both in hypertensive patients and in healthy subjects,
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TABLE 5
REGRESSION ANALYSIS FOR THE DEPENDANT VARIABLE OF AGE-STANDARDIZED SYSTOLIC BLOOD PRESSURE IN RELATION TO
PREDICTORS OF AGE-STANDARDIZED RESISTANCE INDEX, ACCELERATION TIME AND ACCELERATION INDEX FOR HYPERTENSIVE
PATIENTS
Nonstand k Stand. k t p
X SD N B SE Beta
(Constant) –79.44 21.39 –3.714 0.0001
a-s-SBP 143.46 8.31 69
a-s-RI 0.629 0.023 69 364.6 31.43 0.997 11.60 0.0001
a-s-AT 0.031 0.004 69 –105.4 118.17 –0.048 –0.892 0.376
a-s-AI 6.49 0.90 69 –0.476 0.626 –0.052 –0.759 0.45
a-s-SBP – age-standardized systolic blood pressure, a-s-RI – age-standardized resistance index, a-s-AT – age-standardized acceleration
time, a-s-AI – age-standardized acceleration index, SE – standard error, k – coefficient
TABLE 6
REGRESSION ANALYSIS FOR THE DEPENDANT VARIABLE OF AGE-STANDARDIZED SYSTOLIC BLOOD PRESSURE IN RELATION
TO PREDICTORS OF AGE-STANDARDIZED RESISTANCE INDEX, ACCELERATION TIME AND ACCELERATION INDEX FOR HEALTHY
SUBJECTS
Nonstand k Stand. k t p
(Constant)
X SD N B SE Beta
38.44 34.63 1.11 0.271
a-s-SBP 140.98 8.60 65
a-s-RI 0.622 0.024 65 207.8 44.04 0.568 4.72 0.0001
a-s-AT 0.030 0.004 65 2.594 60.98 –0.001 0.043 0.966
a-s-AI 6.77 0.94 65 –3.946 1.11 –0.431 –3.572 0.001
a-s-SBP – age-standardized systolic blood pressure, a-s-RI – age-standardized resistance index, a-s-AT – age-standardized acceleration
time, a-s-AI – age-standardized acceleration index, SE – standard error, k – coefficient
while age-adjusted AT and AI are not significant predic-
tors in hypertensive patients. AI is significant predictor
in healthy examinees. Standardized coefficient b is hi-
gher for RI than for AI (0.57 vs. –0.43). For age-standard-
ized diastolic BP the significant predictor is age-adjusted
resistance index in hypertensive patients, while RI is sig-
nificant predictor also in healthy subjects. AI is also sig-
nificant predictor in healthy examinees, while other pre-
dictors are not statistically significant. Standardized coef-
ficient b is twice higher for RI than for AI (0.66 vs. –0.33).
It was analyzed whether RI in hypertensive patients
with the first stage of EH (140–159/90–99 mm Hg) is sig-
nificantly lower compared to the patients in the second
stage of hypertension (160–179/100–109 mm Hg), and
significance of differences was tested using the t-test.
The descriptive values of RI in hypertensive patients
in the first stage and in the second stage of hypertension,
as well as in healthy examinees, are shown in the Table 9.
T-test has shown that RI values in hypertensive pa-
tients with the first stage of hypertension are statisti-
cally significnatly higher compared to the group of heal-
thy controls (p<0.001), while they are significantly lower
as compared to patients with the second stage of hyper-
tension (p<0.001).
Discussion
In essential hypertension kidneys are inevitably af-
fected with arteriolar pathologic changes, and renal blood
flow may be reduced as a result of arteriolar constriction,
even in the early phase of essential hypertension. Older
patients with essential hypertension have high total pe-
ripheral resistance as a result of atherosclerosis of intra-
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TABLE 7
REGRESSION ANALYSIS FOR THE DEPENDANT VARIABLE OF AGE-STANDARDIZED DIASTOLIC BLOOD PRESSURE IN RELATION
TO PREDICTORS OF AGE-STANDARDIZED RESISTANCE INDEX, ACCELERATION TIME AND ACCELERATION INDEX FOR
HYPERTENSIVE PATIENTS
Nonstand k Stand. k t p
X SD N B SE Beta
(Constant) –56.24 19.61 –2.87 0.006
a-s-DBP 87.73 5.16 69
a-s-RI 0.629 0.023 69 217.32 28.82 0.957 7.54 0.0001
a-s-AT 0.031 0.004 69 152.91 108.3 0.113 1.41 0.966
a-s-AI 6.49 0.90 69 0.4 0.574 0.07 0.694 0.001
a-s-DBP – age-standardized diastolic blood pressure, a-s-RI – age-standardized resistance index, a-s-AT – age-standardized accelera-
tion time, a-s-AI – age-standardized acceleration index, SE – standard error, k – coefficient
TABLE 8
REGRESSION ANALYSIS FOR THE DEPENDANT VARIABLE OF AGE-STANDARDIZED DIASTOLIC BLOOD PRESSURE IN RELATION
TO PREDICTORS OF AGE-STANDARDIZED RESISTANCE INDEX, ACCELERATION TIME AND ACCELERATION INDEX FOR HEALTHY
SUBJECTS
Nonstand k Stand. k t p
X SD N B SE Beta
(Constant) 5.76 21.75 0.265 0.792
a-s-DBP 86.27 5.30 65
a-s-RI 0.622 0.024 65 149.5 27.66 0.663 5.4 0.0001
a-s-AT 0.030 0.004 65 8.21 38.29 –0.006 0.214 0.831
a-s-AI 6.77 0.94 65 –1.87 0.69 –0.331 –2.69 0.009
a-s-DBP – age-standardized diastolic blood pressure, a-s-RI – age-standardized resistance index, a-s-AT – age-standardized accelera-
tion time, a-s-AI – age-standardized acceleration index, SE – standard error, k-coefficient
TABLE 9
THE DESCRIPTIVE VALUES OF RESISTANCE INDICES IN
HYPERTENSIVE PATIENTS IN THE FIRST STAGE AND IN THE
SECOND STAGE OF HYPERTENSION AND IN HEALTHY
EXAMINEES
RI-0 RI-1 RI-2
X 0.590 0.638 0.670
SD 0.023 0.013 0.025
SE 0.003 0.003 0.004
N 65 23 46
RI-0 – resistance index in healthy examinees, RI-1 – resistance
index of patients in the first stage of hypertension, RI-2 – resistance
index of patients in the second stage of hypertension, SE – stan-
dard error, N – number of examinees/patients
renal arteries. Elevated Doppler resistance index in mild
hypertension or in the early phase of essential hyperten-
sion is most probably associated with the functional
vasoconstriction, while in the moderate hypertension
and long-standing hypertension elevated RI may be re-
sult of hypertensive nephrosclerosis16–18. Renal vascular
resistance is regulated by the balance of several vasodila-
tory and vasoconstrictory systems, and any disbalance in
these systems leads to renal vasoconstriction and causes
hypertension12.
Doppler is established noninvasive investigation for
evaluation of flow in renal arteries and veins, and intra-
renal arteries. Duplex Doppler ultrasound has been used
in last fifteen years in numerous studies of renal vascular
resistance in various pathologic renal conditions, and it
was shown that renal resistance index (RI) correlates
highly with blood pressure and renal function18–21. Renal
RI is indicator of renal vascular resistance, and its eleva-
tion reflects well intrarenal vasoconstriction. Elevated
RI is thus observed in conditions like acute renal failure,
acute tubular necrosis, acute and chronic renal trans-
plant rejection, diabetic nephropathy, lupus nephropathy,
hemolitic-uremic syndrom, autosomal policystic kidney
disease, obstructive nephropathy, chronic glomerular and
interstitial renal diseases, etc18–23. Elevated RI is thus as-
sociated with intrarenal arteriolar and glomerular scle-
rosis, and presence and degree of interstitial impairment
in renal parenchymal diseases. RI is considered to be ele-
vated if values are 0.70. RI is also measured in diagnosis
of renal artery stenosis (RAS) and renovascular hyper-
tension, since it is well know that high degree RAS af-
fects morphology of intrarenal arterial spectra, resulting
in parvus-tardus spectra with decreased RI, prolonged ac-
celeration time and decreased acceleration index24.
The role of duplex Doppler ultrasound in evaluation
of renal vascular resistance in essential hypertension is
still not well determined, and relatively few papers were
published, that demonstrated elevated RI with the pro-
gression of hypertension, and good correlation of RI val-
ues with functional renal tests, stage and duration of hy-
pertension, and patient’s age. Since elevation of RI is
associated with macrovascular atherosclerotic changes
in hypertensive patients that also have diabetes, as well
as with increased blood pressure and duration of the dis-
ease in patients with essential hypertension, it is consid-
ered that RI may reflect intraparenchymal impairment
and may serve as indicator of hypertensive renal im-
pairment18–20.
There are only few studies about effects of treatment
with differenct antihypertensive drugs on renal vascular
resistance in patients with essential hypertension25. Ele-
vated RI is partially consequence of functional vascular
changes – vasoconstriction that is result of activation of
sympatic system and circulating noradrenalin or angio-
tensine II, endoteline, prostacycline, and nitric-oxyde.
Therefore, in some cases elevation of RI may be revers-
ible, and potential reversibility was studied during the
treatment with lisinoprile; in many studies it was shown
that ACE inhibitors may protect, and even enhance glo-
merular filtration rate in hypertensive patients. Protec-
tive effect of lisinoprile on renal function may be ex-
plained by the ability of ACE inhibitors to reduce renal
vascular resistance18,26,27. It seems that the choice of
antihypertensive drug affects the outcome of renal im-
pairment in essental hypertension and that the addition
of ACE inhibitors to other drugs results in much better
outcome of renal disease in patients with nephroscle-
rosis28. AT II blockers, like valsartane, have many fa-
vourable effects in addition to lowering of blood pres-
sure; they do not change glomerular filtration, while
they enhance natriuresis. It is assumed that AT II blo-
ckers will ameliorate cardiovascular and renal prognosis
of patients with chronic renal failure29,30.
When renal Doppler was used to evaluate treatment
of hypertension, most commonly resistance index (RI)
was measured, and in few studies PI and peak systolic ve-
locities. Other potentially important parameters of Doppler
spectrum, like acceleration time (AT), acceleration index
(AI), and early systolic peak (ESP) were not studied. AT,
AI and ESP are very important in the assessment of pa-
tients with hemodinamically significant renal artery ste-
nosis and renovascular hypertension. They are affected
also by the vessel compliance, and one might assume that
they may complement Doppler evaluation of renal hemo-
dynamic changes in essential hypertension31. Clinical ap-
plication of these data is important in the evaluation of
therapeutic effects of particular antihypertensive drugs.
Calcium channel blockers were evaluated in several stud-
ies in regard to their influence on renal RI in EH11,32.
There are no published studies about effects of valsar-
tane on renal RI in EH.
RI enables assessment of renal vascular resistance
that provides new hemodynamic parameter in the fol-
low-up of patients with essential hypertension, as well as
evaluation of effects of antihypertensive drugs on kidney.
This study has confirmed the hypothesis that RI in
intrarenal arteries of patients with the newly established
essential hypertension is higher than in healthy exami-
nees. Significanlty higher Ris are observed already in pa-
tients with mild stage of hypertension, which confirms
results of Gale{i} et al.18,26. Positive correlation of RI was
demonstrated with creatinine clearance, left ventricular
mass and age18,33,34.
RI basically represents difference between peak sys-
tolic and enddiastolic velocity, and RI values may be the
same in renal spectra of very different morphology, re-
gardless of substantial differences in AT and AI. Since
AT, AI and ESP were not studied in EH so far, we wanted
to establish whether differences exist in AT and AI val-
ues, and presence of ESP in patients with EH compared
to healthy subjects. We expected that the reduced compli-
ance in hypertensive patients would cause decrease of AI,
increase of AT, and smaller proportion of ESP presence
in hypertensive patients as compared to healthy subjects.
We actually assumed that analysis of multiple parame-
ters of Doppler spectrum may provide more data than
simple ratios of maximal and minimal velocities. ESP
was present in smaller proprotion of hypertensive pa-
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tients (85%) than in control examinees, but these slight
differences have no significance in clinical practice; no
changes in ESP presence were observed after the treat-
ment. ESP can obviously not be used to evaluate efficacy
of treatment with antihypertensives.
Like with RI values, this study demonstrated statisti-
cally significant differences in values of AI and AT be-
tween healthy examinees and patients with EH. AI is sig-
nificantly higher in healthy examinees, while AT is signif-
icantly lower as compared to hypertensive patients. This
confirms the hypothesis that reduced compliance in hy-
pertensive patients reduces AI and prolongs AT.
After six-months of antihypertensive monotherapy
significant reduction of RI was observed, as well as de-
crease of AT and increase of AI in comparison to these
values prior to the treatment. AI values were signifi-
cantly higher after treatment with both valsartane and
niphedipine as compared to the values before therapy. AT
values were also significantly lower after treatment with
both drugs. The hypothesis was confirmed that anti-
hypertensive treatment with both drugs results in the
the reduction of RI, reduction of AT and increase of AI.
Both drugs significantly reduced systolic and diastolic
blood pressure, with no significant difference in the de-
gree of the reduction of systolic and diastolic BP values
between two drugs.
Very important observation is that after six months of
treatment RI values in patients treated with valsartane
(RI=0.615±0.036) are significantly lower than RI values
in patients treated with niphedipine (RI=0.642±0.030)
(p<0.01). Although both drugs significantly reduced RI
in interlobar arteries, valsartane had stronger effect in
comparison to niphedipine, which demonstrates that
vaslartane has better therapeutic effect on kidney than
niphedipine, although there is no significant difference
in two drugs in the degree of lowering systolic and dia-
stolic blood pressure. Therefore the observed effect on RI
may be independant on blood pressure.
Also, significant differences between patients treated
with two drugs were demonstrated in AI values; valsar-
tane treated patients had (AI=6.5±1.42) statistically sig-
nificantly lower that patients treated with niphedipine
(AI=5.7±1.55) (p<0.03). Like in the case of RI, these re-
sults indicate that vaslartane has better therapeutic ef-
fect on kidney that niphedipine. The lack of significant
differences in AT values between patients treated with
two drugs is most probably due to the fact that AT mea-
surement is very dependant upon examiner, and errors
in measurement are more pronounced than in AI or RI
measurements. Latter two parameters are measured au-
tomatically after positioning of callipers, while in AI
manual measurement of a very small distance is needed.
Apparently RI is the best Doppler parameter that in-
dicates efficacy of a particular drug. AI may be used
also, while AT measurements do not seem to be very
useful.
Hypertension is responsible for important renal im-
pairment in many patients, but the level of blood pres-
sure is not a reliable predictor of the outcome of renal
disease. Therefore it is hard to select patients with high
risk for renal disease amnog many hypertensive patients.
Microalbuminuria is a well known marker of subclinical
impairment of organs and predictor of total cardiovascu-
lar mortality in patients with primary hypertension35.
Some studies established correlation between microalbu-
minuria and increased RI in patients with essential hy-
pertension who have impaired renal function18,27,36. Sal-
veti demonstrated positive correlation of microalbuminuria
and renal vascular resistance in hypertensive patients,
since RI reflects renal vasoconstriction37. There are no
studies about prognostic significance of increased renal
RI. Leoncini demonstrated that lisinoprile was superior
to niphedipine in the reduction of albuminuria and long-
-term reduction of RI25. They conclude that ACE inhibi-
tors have better renoprotective effects.
One might conclude that the ideal renoprotective
drug in addition to lowering of blood pressure has to in-
crease perfusion of kidney by lowering of vascular resis-
tance. Patients studied in this paper did not have micro-
albuminuria associated with hypertensive renal disease.
Patients did not have left ventricular hypertrophy on
ECG, or hypertensive changes of ocular fundus. Al-
though relatively small number of patients was studied,
we may speculate that changes of renal vascular resis-
tance demonstrated by Doppler US represent earliest al-
terations that can be observed noninvasively, that may
still be reversible. To confirm this hypothesis studies on
large number of patients are needed.
There are several shortcomings for the routine clini-
cal use of color duplex Doppler US for monitoring effi-
cacy of therapy of essential hypertension with various
medications. Primarilly these are very long examina-
tions, that require very accurate measurements and ex-
aminers have to be very concentrated. Changes of all
measured parameters are in a quite small range of only
10–15%, and accuracy in measurements is thus manda-
tory. Interlobar arteries have to be studied in three dif-
ferent parts of the kidney and optimal spectra have to be
obtained. Mean value is calculated from all measure-
ments. These time-consuming measuremnts are incon-
venient for everyday clinical practice, and can be used
only for research. Routinely for indications like diabetic
nephropahty or ADPKD evaluation, RI is measured after
the quick insonation of 2–3 arteries, after good spectra
are obtained. But to evaluate effects of antihypertensive
drugs on renal Doppler parametrs measurements have to
be meticulous. The quality of results also depends con-
siderably on the quality of the US scanner; in our opinion
only high-end systems should be used for these studies,
and these scanners are not very common in hospitals.
Also, ultrasound is known to be operator dependant, and
large »interobserver variability« exists between various
examiners. In studies of this type it is advisable that all
measurements are performed by only one well educated
examiner.
In spite of all shortcomings, this study demonstrated
that relatively simple Doppler parameter like resistance
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index significantly correlates with all parameters stud-
ied, and reflects well the effects of antihypertensive med-
ications for lowering of renal vascular resistance in es-
sential hypertension. Additional Doppler parameters like
AI, AT and ESP do not have a real significance in the as-
sessment of efficacy of various antihypertensive drugs.
Although AI was shown to have certain use in evaluation
of efficacy of drugs, RI was better predictor than AI in re-
gression analyisis. Therefore, RI seems to be sufficient
among Doppler parameters to evaluate antihypertensive
drugs effects on kidneys.
Conclusion
Renal RI is the best Doppler parameter to study ther-
apeutic effects of antihypertensive monotherapy on kid-
ney in essential hypertension. Doppler parameters other
than RI seem not to have the practical clinical value.
More favourable effect on renal vascular resistance (i.e.
resistance index) of valsartane in comparison to niphedi-
pine was demonstrated. Similar studies for assesing effi-
cacy of other antihypertensive drugs may be conducted,
using resistance index.
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UTJECAJ ATII BLOKATORA I BLOKATORA KALCIJSKIH KANALA NA BUBRE@NI KRVO@ILNI
OTPOR U BOLESNIKA S ESENCIJALNOM HIPERTENZIJOM
S A @ E T A K
Dopler je koristan u procjeni bubre`nog krvo`ilnog otpora, a indeks otpora (RI) korelira zna~ajno s krvnim tlakom i
funkcijom bubrega u brojnim patolo{kim stanjima. Cilj je izmjeriti i usporediti bubre`ne doplerske indekse kod bo-
lesnika s novodijagnosticiranom esencijalnom hipertenzijom (EH) i zdravih osoba; odrediti promjene doplerskih in-
deksa u bolesnika nakon {estomjese~ne monoterapije ili AT II blokatorom (valsartan) ili blokatorom kalcijskih kanala
(nifedipin); odrediti koji lijek ima bolji renoprotektivni u~inak. Pregledano je 65 zdravih osoba i 69 bolesnika s novo-
dijagnosticiranom EH bez znakova o{te}enja ciljnih organa. Dupleks dopler ultrazvukom intrarenalnih interlobarnih
arterija izmjereni su RI, akceleracijski indeks (AI) i akceleracijsko vrijeme (AT). Antihipertenzivna monoterapija je
provedena valsartanom u 34 bolesnika, a nifedipinom u 35 bolesnika. Dopler je ponovljen nakon provedene {estomjese-
~ne terapije. RI u bolesnika s prvim stadijem EH je zna~ajno vi{i u usporedbi sa zdravim ispitanicima (p<0,001), a
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zna~ajno ni`i u usporedbi s drugim stadijem EH (p<0,001). Zna~ajan pad sistoli~kog (p<0,001) i dijastoli~kog krvnog
tlaka (KT) (p<0,001) je uo~en nakon lije~enja. RI u zdravih ispitanika (RI=0,59±0,023) je zna~ajno ni`i nego kod EH
(RI=0,66±0,26) (p<0,001), dok je AI zna~ajno vi{i (p<0,001), a AT zna~ajno ni`e (p<0,001). U bolesnika lije~enih i
valsartanom i nifedipinom vrijednosti RI su zna~ajno ni`e nego prije lije~enja (p<0,001), vrijednosti AI su zna~ajno vi{e, a
AT zna~ajno ni`e, i to nakon lije~enja s oba lijeka. RI nakon lije~enja kod bolesnika lije~enih valsartanom (RI=0,615±0,036)
je zna~ajno ni`i od RI kod bolesnika lije~enih nifedipinom (RI=0,642±0,030) (p<0,01). Regresijska analiza za predik-
tivne vrijednosti RI, AT, AI u odnosu na dobno-standardizirani sistoli~ki i dijastoli~ki KT zdravih ispitanika i hipertoni-
~ara pokazala je da je RI najja~i i statisti~ki zna~ajan prediktor u svim skupinama ispitanika. [estomjese~na monote-
rapija EH valsartanom ili nifedipinom je jednako djelotvorna u smanjenju krvnog tlaka, ali valsartan ima bolje dje-
lovanje na bubreg. Indeks otpora u intrarenalnim arterijama je najbolji parametar doplerskog spektra u procjeni dje-
lovanja antihipertenziva na bubreg.
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